The prognosis of oncogenic-addicted NSCLC has been transformed due to the development of targeted therapies, firstly inhibiting the mutant epidermal growth factor receptor (EGFR) [2,3], then ALK [4,5,6] and ROS1 rearrangement [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.